20Med Therapeutics Appoints Industry Veteran Hugo Fry as Chief Business Officer to Expedite mRNA Vaccine Delivery Platform Program
29 nov. 2023 03h00 HE
|
20MED Therapeutics B.V.
Leiden, The Netherlands, November 29, 2023 – 20Med Therapeutics, a leader in non-viral delivery of mRNA vaccines, today announced the appointment of Hugo Fry as Chief Business Officer. His appointment...
Drug Product Filled with Berkshire Sterile’s Low Loss Fill Process Receives FDA Greenlight
18 mai 2023 13h00 HE
|
Berkshire Sterile Manufacturing
Lee, MA, May 18, 2023 (GLOBE NEWSWIRE) -- RNAimmune, a biotech company focused on developing groundbreaking mRNA therapies, recently received FDA approval to begin Phase 1 clinical studies for an...
Berkshire Sterile debuts its innovative “low loss” GMP fill process
28 mars 2023 10h00 HE
|
Berkshire Sterile Manufacturing
Lee, MA, March 28, 2023 (GLOBE NEWSWIRE) -- Berkshire Sterile Manufacturing (BSM), a fill finish CDMO located in Lee, MA, recently completed their first GMP fill using their new low loss fill...
LEON successfully completes development of its innovative reactor for more efficient production of lipid nanoparticles
03 janv. 2023 09h00 HE
|
leon-nanodrugs GmbH
LEON achieved superior accuracy in development of its proprietary reactor, facilitating exceptional inter-device reproducibility of particle size and distribution, and thus seamless process transfer,...
IMUNON Enters into Technology Evaluation Agreement with Acuitas Therapeutics to Evaluate IMUNON’s PLACCINE Plasmid DNA with Acuitas’ Lipid Nanoparticle Delivery System
10 nov. 2022 08h30 HE
|
Imunon, Inc.
Successful combination of technologies will expand the opportunities for IMUNON’s DNA-based modality and broaden applications for the PLACCINE nucleic acid vaccine platform as an alternative to mRNA...
Harro Höfliger and LEON collaborate to bring the innovative NANOus LNP-encapsulation device to market for rapid, large-scale prophylactic vaccine manufacturing
26 oct. 2022 05h00 HE
|
Leon-nanodrugs GmbH
LEON and Harro Höfliger to build and commercialize LEON’s NANOus, a novel aseptic manufacturing device to facilitate commercial production of LNP-encapsulated genetic materials and other APIsBy...
RespireRx Pharmaceuticals Inc. Announces Patent Filings Claiming Novel Lipid Based Formulations for Insoluble Compounds, Including Cannabinoids Such as Dronabinol
23 mars 2022 08h00 HE
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., March 23, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and...
Letter to Stockholders and Other Stakeholders: A Brief Summary of Our Progress During Past Twelve Months and a Peek Looking Forward
07 mars 2022 08h00 HE
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., March 07, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and...
Exavir Therapeutics announces preclinical data demonstrating complete elimination of HIV from human cells with LNP-delivered Tat-targeted CRISPR-Cas9
10 nov. 2021 07h30 HE
|
Exavir Therapeutics
Early candidate from XVIR-TAT series demonstrated genetic elimination of HIV and robust anti-retroviral activity with CRISPR-Cas9 based excision Exavir lipid nanoparticles (LNPs) with mRNA...
Exavir Therapeutics announces publication of preclinical data for novel tenofovir prodrug, XVIR-210, in Nature Communications, demonstrating long-acting exposures sufficient for antiviral activity against HIV and HBV
16 sept. 2021 07h30 HE
|
Exavir Therapeutics
With a single administration, XVIR-210, a nano-formulated prodrug of tenofovir, provided drug levels sufficient for chronic HBV treatment, HIV treatment, and HIV prophylaxis for over two months in...